Article
Novel mRNA isoforms and mutations of uridine monophosphate synthetase and 5-fluorouracil resistance in colorectal cancer.
The pharmacogenomics journal - 1 Apr 2013
Griffith M, Mwenifumbo J C, Cheung P Y, Paul J E, Pugh T J, Tang M J, Chittaranjan S, Morin R D, Asano J K, Ally A A, Miao L, Lee A, Chan S Y, Taylor G, Severson T, Hou Y-C, Griffith O L, Cheng G S W, Novik K, Moore R, Luk M, Owen D, Brown C J, Morin G B, Gill S, Tai I T, Marra M A
Abstract excerpt
The drug fluorouracil (5-FU) is a widely used antimetabolite chemotherapy in the treatment of colorectal cancer. The gene uridine monophosphate synthetase (UMPS) is thought to be primarily responsible for conversion of 5-FU to active anticancer metabolites in tumor cells. Mutation or aberrant expression of UMPS may contribute to 5-FU resistance during treatment. We undertook a characterization of UMPS mRNA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.